Skip to main content

Infections

12
Pipeline Programs
18
Companies
19
Clinical Trials
4 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
2
1
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 19 programs with unclassified modality

On Market (1)

Approved therapies currently available

B. Braun
CEFAZOLIN AND DEXTROSEApproved
cefazolin sodium
B. Braun
injection2000

Competitive Landscape

18 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
1
1
Ceftaroline fosamilPhase 41 trial
Ceftaroline fosamilPhase 2/31 trial
Active Trials
NCT01530763Completed161Est. Jul 2014
NCT01645735Completed49Est. Dec 2013
B. Braun
B. BraunGermany - Melsungen
1 program
1
CEFAZOLIN AND DEXTROSE(Cefazolin)Phase 44 trials
Active Trials
NCT05205486Completed12Est. Jul 2023
NCT03231228Terminated61Est. Jul 2019
NCT01904357Completed12Est. Sep 2013
+1 more trials
Sandoz
SandozAustria - Kundl
2 programs
1
DaptomycinPhase 31 trial
Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLCPHASE_11 trial
Active Trials
NCT00875966Completed42Est. Oct 2004
NCT01184872Completed120Est. Mar 2011
MSD
MSDIreland - Ballydine
1 program
1
MK0826, ertapenem sodiumPhase 21 trial
Active Trials
NCT00092170Completed100Est. Jan 2004
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MK0826, ertapenem sodiumPhase 2
Arrowhead Pharmaceuticals
1 program
1
Azithromycin PillPhase 11 trial
Active Trials
NCT06543290Recruiting400Est. Aug 2026
JSC Valenta Pharmaceuticals
1 program
1
HydroxymethylquinoxalindioxydePhase 11 trial
Active Trials
NCT05505097Completed16Est. Dec 2022
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
MMV367 3mgPhase 1
Bayer
BayerLEVERKUSEN, Germany
1 program
1
MoxifloxacinPhase 1Small Molecule1 trial
Active Trials
NCT01049022Completed31Est. Aug 2013
Theravance Biopharma
1 program
1
TD-1607Phase 11 trial
Active Trials
NCT01949103Completed48Est. Jul 2014
Philips
PhilipsNetherlands - Amsterdam
1 program
Multidisciplinary TeamN/A1 trial
Active Trials
NCT05471973Recruiting200Est. Dec 2026
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome N/A1 trial
Active Trials
NCT00006150Recruiting600
Rhythm Pharmaceuticals
1 program
Silverlon®N/A1 trial
Active Trials
NCT02781779Completed147Est. Dec 2017
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Silverlon®N/A
GSK
GSKLONDON, United Kingdom
1 program
MMV367 3mgPHASE_11 trial
Active Trials
NCT05979207Completed12Est. Oct 2023
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
Meropenem-PralubactamPHASE_11 trial
Active Trials
NCT07124468Recruiting16Est. Feb 2026
Chia Tai TianQing Pharmaceutical Group
1 program
The injectable TQD3606PHASE_11 trial
Active Trials
NCT05340530Unknown56Est. Dec 2023
Novartis
NovartisBASEL, Switzerland
1 program
DaptomycinPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
B. BraunCefazolin
AstraZenecaCeftaroline fosamil
SandozDaptomycin
AstraZenecaCeftaroline fosamil
MSDMK0826, ertapenem sodium
Qilu PharmaceuticalMeropenem-Pralubactam
Arrowhead PharmaceuticalsAzithromycin Pill
GSKMMV367 3mg
JSC Valenta PharmaceuticalsHydroxymethylquinoxalindioxyde
B. BraunCefazolin
Chia Tai TianQing Pharmaceutical GroupThe injectable TQD3606
Theravance BiopharmaTD-1607
B. BraunCefazolin
BayerMoxifloxacin
B. BraunCefazolin

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 2,107 patients across 19 trials

Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects

Start: Nov 2017Est. completion: Jul 201961 patients
Phase 4Terminated
NCT01645735AstraZenecaCeftaroline fosamil

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Start: Oct 2012Est. completion: Dec 201349 patients
Phase 4Completed

Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

Start: Mar 2010Est. completion: Mar 2011120 patients
Phase 3Completed
NCT01530763AstraZenecaCeftaroline fosamil

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

Start: Sep 2012Est. completion: Jul 2014161 patients
Phase 2/3Completed
NCT00092170MSDMK0826, ertapenem sodium

An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

Start: Mar 2002Est. completion: Jan 2004100 patients
Phase 2Completed
NCT07124468Qilu PharmaceuticalMeropenem-Pralubactam

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

Start: Sep 2025Est. completion: Feb 202616 patients
Phase 1Recruiting

Azithromycin Before Induction

Start: Aug 2023Est. completion: Aug 2026400 patients
Phase 1Recruiting
NCT05979207GSKMMV367 3mg

Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum

Start: Aug 2023Est. completion: Oct 202312 patients
Phase 1Completed
NCT05505097JSC Valenta PharmaceuticalsHydroxymethylquinoxalindioxyde

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Start: May 2022Est. completion: Dec 202216 patients
Phase 1Completed

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

Start: Apr 2022Est. completion: Jul 202312 patients
Phase 1Completed

To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

Start: Apr 2022Est. completion: Dec 202356 patients
Phase 1Unknown

TD-1607 MAD Study in Healthy Subjects

Start: Oct 2013Est. completion: Jul 201448 patients
Phase 1Completed

Pediatric Cefazolin PK Study

Start: Mar 2013Est. completion: Sep 201312 patients
Phase 1Completed
NCT01049022BayerMoxifloxacin

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Start: May 2010Est. completion: Aug 201331 patients
Phase 1Completed

Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX

Start: Dec 2009Est. completion: Feb 201024 patients
Phase 1Completed
NCT00875966SandozAzithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC

Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

Start: Aug 2004Est. completion: Oct 200442 patients
Phase 1Completed
NCT05471973PhilipsMultidisciplinary Team

CIED Infection Quality Initiative Demonstration Project

Start: May 2023Est. completion: Dec 2026200 patients
N/ARecruiting

Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant

Start: Jun 2016Est. completion: Dec 2017147 patients
N/ACompleted
NCT00006150Allergy TherapeuticsNatural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

Start: Aug 2000600 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 2,107 patients
18 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.